Consensus Prothena Corporation plc

Equities

PRTA

IE00B91XRN20

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
20.56 ^USD	0.00%		-2.10%	-43.42%

Mar. 04	Prothena Names David Ford as Chief People Officer	MT
Mar. 04	Prothena Appoints David Ford to Newly Created Chief People Officer	CI

Evolution of the average Target Price on Prothena Corporation plc

Price target over the last 5 years

History of analyst recommendation changes

eca3e6ca3a32209026e.ks9PkOSI_KUZaiJ96S71BDmU41twce2HMcRN2-ZbPE0.xoY99tLRhuxQAWEYnEOwQGvErDlIC4DzRZcrnqcVcy7Fpwj9lurJ7CpaTQ~7697342fde9c18fbe667393e6fbc7e17

Analyst Recommendations on Prothena Corporation plc

Oppenheimer Cuts Prothena Price Target to $80 From $98, Maintains Outperform Rating	Feb. 20	MT
RBC Trims Price Target on Prothena to $35 From $36, Keeps Sector Perform, Speculative Risk	Feb. 16	MT
RBC Cuts Price Target on Prothena to $36 From $43, Calls Initial Data on PRX012 'Anticlimactic,' Keeps Sector Perform, Speculative Risk	Jan. 25	MT
Deutsche Bank Initiates Coverage on Prothena With Buy Rating, $62 Price Target	Dec. 12	MT
RBC Cuts Price Target on Prothena to $43 From $60, Keeps Sector Perform, Speculative Risk	Nov. 02	MT
JMP Securities Adjusts Prothena's Price Target to $83 From $82, Keeps Market Outperform Rating	23-08-04	MT
Cantor Fitzgerald Adjusts Prothena Price Target to $120 From $98, Maintains Overweight Rating	23-05-08	MT
HC Wainwright Adjusts Price Target on Prothena to $90 From $75, Maintains Buy Rating	23-05-05	MT
RBC Boosts Price Target on Prothena to $60 From $55, Maintains Sector Perform, Speculative Risk	23-05-05	MT
SVB Securities Starts Prothena at Outperform With $80 Price Target	23-04-24	MT
Citigroup Adjusts Price Target on Prothena to $72 From $76, Keeps Buy Rating	23-02-27	MT
RBC Trims Price Target on Prothena to $55 From $56, Keeps Sector Perform, Speculative Risk	23-02-24	MT
Piper Sandler Starts Prothena at Overweight With $94 Price Target	23-01-27	MT
RBC Lifts Price Target on Prothena to $56 From $55, Maintains Sector Perform Rating	23-01-13	MT
Cantor Fitzgerald Adjusts Price Target on Prothena to $98 From $91, Maintains Overweight Rating	22-12-21	MT
Oppenheimer Adjusts Prothena Price Target to $120 From $110, Maintains Outperform Rating	22-11-15	MT
RBC Downgrades Prothena to Sector Perform From Outperform, Citing Valuation, Lifts Price Target to $55 From $52, Keeps Speculative Risk Qualifer	22-11-04	MT
Citigroup Adjusts Prothena's Price Target to $71 From $65, Reiterates Buy Rating	22-10-24	MT
Oppenheimer Adjusts Prothena Price Target to $110 From $100, Maintains Outperform Rating	22-09-29	MT
BofA Securities Upgrades Prothena to Buy from Neutral, Adjusts Price Target to $65 from $45	22-09-28	MT
JMP Securities Adjusts Price Target on Prothena to $81 From $50, Maintains Market Outperform Rating	22-09-28	MT
RBC Lifts Price Target on Prothena to $52 From $45, Says Biogen/Eisai's Lecanemab Data Clear Way for Anti-Amyloid Drug Class in Alzheimer's; Outperform, Speculative Risk Kept	22-09-28	MT
JMP Securities Adjusts Prothena's Price Target to $50 from $77, Keeps Market Outperform Rating	22-05-25	MT
RBC Slashes Price Target on Prothena to $45 From $82, Keeps Outperform-Speculative Risk Rating	22-05-02	MT
JMP Securities Starts Prothena at Market Outperform With $77 Price Target	21-11-19	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

20.56 USD

Average target price

66.09 USD

Spread / Average Target

+221.45%

High Price Target

94 USD

Spread / Highest target

+357.20%

Low Price Target

34 USD

Spread / Lowest Target

+65.37%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Prothena Corporation plc

Oppenheimer
RBC Capital Markets
Deutsche Bank Securities
JMP Securities
Cantor Fitzgerald
HC Wainwright
SVB Securities LLC
Citigroup
Piper Sandler
BofA Securities
Fox Advisors
BTIG
Jefferies & Co.

Ratings for Prothena Corporation plc

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar